Virchow, formerly Corramedical, manufactures the Crow’s Nest Biopsy Catchment System and operates the Virchow Vault, a CAP-accredited liquid specimen biorepository that stores Liquid Companion Specimens (LCSs) produced after core needle tumor biopsies. The company supplies hospitals with a monthly provision of Crow’s Nest units and allows oncologists to order genomic sequencing or other molecular testing via virchowvault.com without needing formalin-fixed tissue blocks. Clinical concordance studies at six U.S. institutions compare molecular results from standard FFPE tissue to LCSs and are cited by the company as evidence of the technology’s clinical value. Virchow positions its offering as addressing tissue insufficiency and reducing the need for repeat biopsies by preserving otherwise discarded material. The recent $4 million seed financing will fund completion of the Virchow Vault and expansion of Biopsy Catchment pilot programs at additional U.S. medical centers. The company is an EvoNexus portfolio company and is led by CEO Alexander Arrow, MD.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2026